EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy

Takeshi Hatanaka iD, Yutaka Yata, Atsushi Naganuma iD, Satoru Kakizaki iD

Cancers · 16.03.2023 · 15 (6) · 1798

DOI: 10.3390/cancers15061798 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.03.2023. Verfasst von Takeshi Hatanaka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transarterial chemoembolization (TACE) has been standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, all intermediate-stage HCC patients did not benefit from TACE treatment because intermediate-stage HCC encompasses a wide variety of HCCs. Owing to remarkable progress in systemic therapy, including molecular-targeted therapy for advanced-stage HCC, the standard treatment of HCC has recently shifted to systemic therapy. However, it remains controversial as to which treatment should be initially performed for intermediate-stage HCC. In addition, although curative treatment can be considered when the tumor shrinks, the timing of conversion therapy remains uncertain. This review summarizes the advances of HCC treatment and discusses treatment strategies for intermediate-stage HCC.

Schlagwörter

Stichwörter der Autor:innen

TACE inappropriateTACE refractoryatezolizumab plus bevacizumabconversion therapydurvalumab plus tremelimumabhepatocellular carcinomaimmune checkpoint inhibitorintermediate-stage hepatocellular carcinomamolecular-targeted therapytransarterial chemoembolizationtyrosine kinase inhibitorup-to-7 criteria

Autor:innen und Institutionen

  • Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi 371-0821, Japan.
  • Department of Gastroenterology, Hanwa Memorial Hospital, Osaka 558-0041, Japan.
  • Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.
  • Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, Japan.

ORCID-Profile: Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki

Zitieren

APA

Hatanaka, T., Yata, Y., Naganuma, A., & Kakizaki, S. (2023). Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers, 15(6), 1798. https://doi.org/10.3390/cancers15061798

Vancouver

Hatanaka T, Yata Y, Naganuma A, Kakizaki S. Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy. Cancers. 2023;15(6):1798. doi:10.3390/cancers15061798

BibTeX
@article{Hatanaka2023,
  author = {Hatanaka, Takeshi and Yata, Yutaka and Naganuma, Atsushi and Kakizaki, Satoru},
  title = {Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1798},
  doi = {10.3390/cancers15061798}
}
Kostenlos starten →